Guan Yin, Xu Bing-He, Li Qing, Zhang Pin, Zhao Long-Mei, Yuan Peng, Wang Jia-Yu
Department of Medical Oncology, Cancer Institute & Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China.
Zhonghua Yi Xue Za Zhi. 2008 Jan 8;88(2):77-81.
To analyze the clinical characteristics, survival, and prognosis of female breast cancer patients with 10 or more positive lymph nodes.
The data of 128 female breast cancer patients with 10 or more positive lymph nodes from JAN 1998 to Mar 2002 were retrospectively reviewed. The clinical characteristics, survival, and prognostic factors were analyzed by SPSS 10.0 statistic software.
The 1-, 3-, 5, and 7-year overall survival (OS) rates were 91.4%, 68.8%, 53.1%, and 40.2%, and the disease free survival (DFS) rates were 80.9%, 54.1%, 44.7%, and 36.0% respectively. Log Rank test showed that tumor size was not related to prognosis; patients with more than 20 positive lymph nodes (P = 0.029), positive lymph node ratio greater than 0.8 (P = 0.027), and infiltration of vessel (P = 0.037) had a poorer DFS and shorter OS; patients with negative hormonal receptor had a poorer OS than those with positive hormonal receptor (P = 0.019); radiotherapy improved DFS (P = 0.000), and adjuvant chemotherapy for 4 - 6 cycles (P = 0.000) or more than 6 cycles (P = 0.004) and endocrine therapy (P = 0.001) might improve DFS and OS; patients with multiple metastasis had a poorer survival than those with local recurrence (P = 0.004) and single metastasis (P = 0.058). COX proportional hazard model analysis showed that positive lymph node ratio and infiltration of vessel were independent prognostic factors for both DFS and OS; adjuvant endocrine therapy decreased relapse and death hazard ratio for 43% (RR = 0.57, P = 0.035) and 65% (RR = 0.35, P = 0.000) respectively; adjuvant radiotherapy decreased the relapse hazard ratio for 72% (RR = 0.28, P = 0.000); and adjuvant chemotherapy for more than 4 cycles decreased death hazard ratio for 51% (RR = 0.49, P = 0.001); patients with recurrence and/or metastasis had a higher death hazard ratio (RR = 2.738, P = 0.000), hormonal receptor was an independent prognostic factor, and active treatment might improve the survival.
Breast cancers with 10 or more positive lymph nodes have higher aggressively biologic characteristics; the prognosis of this subgroup has no relationship with tumor size and inverse correlation with the numbers of positive lymph nodes; Positive lymph node ratio and infiltration of vessel are important independent factors. Multidiscipline therapy including adjuvant radiotherapy, endocrine therapy, and at least 4 cycles chemotherapy increases the therapeutic effect, decreases relapse and death hazard ratio, and improves the survival.
分析腋窝淋巴结转移≥10枚女性乳腺癌患者的临床特征、生存及预后情况。
回顾性分析1998年1月至2002年3月收治的128例腋窝淋巴结转移≥10枚女性乳腺癌患者的临床资料,采用SPSS 10.0统计软件进行临床特征、生存及预后因素分析。
全组患者1、3、5、7年总生存率分别为91.4%、68.8%、53.1%、40.2%;无病生存率分别为80.9%、54.1%、44.7%、36.0%。Log Rank检验显示肿瘤大小与预后无关;腋窝淋巴结转移>20枚(P=0.029)、腋窝淋巴结转移率>0.8(P=0.027)及脉管浸润(P=0.037)患者无病生存期和总生存期较短;激素受体阴性患者总生存期较阳性患者短(P=0.019);放疗可提高无病生存率(P=0.000),辅助化疗4~6周期(P=0.000)或>6周期(P=0.004)及内分泌治疗(P=0.001)可提高无病生存率和总生存率;多发转移患者生存率低于局部复发(P=0.004)和单发转移患者(P=0.058)。COX模型分析显示腋窝淋巴结转移率和脉管浸润是影响无病生存期和总生存期的独立预后因素;辅助内分泌治疗可使复发风险和死亡风险分别降低43%(RR=0.57,P=0.035)和65%(RR=0.35,P=0.000);辅助放疗可使复发风险降低72%(RR=0.28,P=0.000);辅助化疗>4周期可使死亡风险降低51%(RR=0.49,P=0.001);复发和/或转移患者死亡风险高(RR=2.738,P=0.000),激素受体是独立预后因素,积极治疗可改善生存。
腋窝淋巴结转移≥10枚女性乳腺癌具有较高侵袭性生物学行为,该亚组患者预后与肿瘤大小无关,与腋窝淋巴结转移数呈负相关,腋窝淋巴结转移率和脉管浸润是重要的独立预后因素,辅助放疗、内分泌治疗及至少4周期化疗的多学科综合治疗可提高疗效,降低复发风险和死亡风险,改善生存。